Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

被引：0
|
作者：
Thorne, J. Carter [1 ]
Boire, Gilles [2 ]
Chow, Andrew [3 ]
Garces, Kirsten [4 ]
Liu, Fang [5 ]
Poulin-Costello, Melanie [4 ]
Walker, Valery [5 ]
Haraoui, Boulos [6 ]
机构：
[1] Southlake Reg Hlth Ctr, Newmarket, ON, Canada
[2] Univ Sherbrooke, Dept Med, Div Rheumatol, Sherbrooke, PQ J1K 2R1, Canada
[3] Credit Valley Rheumatol, Mississauga, ON, Canada
[4] Amgen Canada Inc, Mississauga, ON, Canada
[5] Optum, Burlington, ON, Canada
[6] Inst Rhumatol Montreal, Montreal, PQ, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
548
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Drug-survival, effectiveness and safety of infliximab, adalimumab and etanercept in rheumatoid arthritis patients
    Flendrie, M.
    Creemers, M. C. W.
    Welsing, P. M. J.
    Van den Hoogen, F. H. J.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 191 - 191
  • [32] Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
    Pappas, Dimitrios
    O'Brien, Jacqueline
    Kelleman, Mike
    Guo, Lin
    Shan, Ying
    Baker, Joshua
    Kricorian, Greg
    Stryker, Scott
    Collier, David
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2798 - 2800
  • [33] Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
    Bonafede, Machaon
    Watson, Crystal
    Joseph, George
    Princic, Nicole
    Harrison, David J.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S778 - S778
  • [34] Drug Survival and Long-Term Dose Comparison of Etanercept and Infliximab in Rheumatoid Arthritis Patients
    Hanna, Brian D.
    Shah, Alpesh
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S477 - S477
  • [35] A cost-efficacy comparison of adalimumab and etanercept in the treatment of rheumatoid arthritis
    Malone, DC
    Singh, A
    Wanke, LA
    Ortmeier, BG
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 537 - 537
  • [36] Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First-or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept.
    Johnston, S.
    Lobo, F.
    McMorrow, D.
    Fowler, R.
    Smith, D.
    Nadkarni, A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S40 - S40
  • [37] The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
    Incerti, Devin
    Hernandez, Ervant J. Maksabedian
    Tkacz, Joseph
    Jansen, Jeroen P.
    Collier, David
    Gharaibeh, Mahdi
    Moore-Schiltz, Laura
    Stolshek, Bradley S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (10): : 1236 - 1242
  • [38] Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    Rahman, Mahboob U.
    Strusberg, Ingrid
    Geusens, Piet
    Berman, Alberto
    Yocum, David
    Baker, Daniel
    Wagner, Carrie
    Han, John
    Westhovens, Rene
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1233 - 1238
  • [39] IMPROVED QUALITY OF LIFE AND PRODUCTIVITY IN PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS ACTIVELY SWITCHED TO TREATMENT WITH INFLIXIMAB FROM ADALIMUMAB OR ETANERCEPT THERAPY
    Fleischmann, Roy
    Bolce, Rebecca
    Wang, Jianping
    Ingham, Mike
    Dehoratius, Ralph
    Decktor, Dennis
    RHEUMATOLOGY, 2012, 51 : 138 - 138
  • [40] Dose Escalation Among Rheumatoid Arthritis Patients Treated with Infliximab or Abatacept: Comparison in Claims Data
    Darkow, Theodore
    Chastek, Benjamin
    Rosenblatt, Lisa
    Trivedi, Digisha
    Hebden, Tony
    Henk, Henry
    Liu, Fang
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S476 - S476
12345